feed,title,long_url,short_url
MedRxiv,"Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial",https://medrxiv.org/cgi/content/short/2023.07.05.23291954v1?rss=1,https://da.gd/PMw3IN
